ACM
MRNA icon

Ayrshire Capital Management’s Moderna MRNA Stock Holding History

Ayrshire Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,855
Closed -$2.05M – 51
2023
Q3 		$2.05M Buy
+19,855
New +$2.21M 1.33% 31

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ayrshire Capital Management's MRNA Position: Q4 2023 in Review

Ayrshire Capital Management sold out of Moderna (MRNA) in Q4 2023, closing a stake of 19,855 shares — an estimated $2.05M sold.

Ayrshire Capital Management first reported a position in MRNA in Q3 2023 and held it in 1 quarter. The position peaked at $2.05M in Q3 2023. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Ayrshire Capital Management reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Ayrshire Capital Management sold 19,855 Moderna shares in Q4 2023, an estimated $2.05M.
  • Ayrshire Capital Management first reported a position in Moderna in Q3 2023 and held it in 1 quarter.
  • Ayrshire Capital Management's Moderna position peaked at $2.05M in Q3 2023.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Ayrshire Capital Management's 13F filing for Q4 2023, filed 9 Jan 2024.